Abstract: This invention relates to processes and systems for converting acyclic hydrocarbons to alkenes, cyclic hydrocarbons and/or aromatics, for example converting acyclic C5 hydrocarbons to cyclopentadiene in a reactor system. The process includes contacting a feedstock comprising acyclic hydrocarbons with a catalyst material and an inert material to convert at least a portion of the acyclic hydrocarbons to a first effluent comprising alkenes, cyclic hydrocarbons and/or aromatics. In particular, the catalyst material and the inert material have a different average diameter and/or density providing varying fluidization behavior in the reactor.

Abstract: A process utilizing an ionic liquid is described. The process includes contacting a hydrocarbon feed with an ionic liquid component, the ionic liquid component comprising a mixture of a first ionic liquid and a viscosity modifier, wherein a viscosity of the ionic liquid component is at least about 10% less than a viscosity of the first ionic liquid.

Abstract: Fluidizable catalysts for the gas phase oxygen-free oxidative cracking of alkanes, such as hexane, to one or more olefins, such as ethylene, propylene, and/or butylene. The catalysts comprise 1-15% by weight per total catalyst weight of one or more vanadium oxides (VOx), such as V2O5. The catalysts are disposed on an alumina support that is modified with cerium to influence catalyst acidity and characteristics of lattice oxygen at the catalyst surface. Various methods of preparing and characterizing the catalyst as well as methods for the gas phase oxygen free oxidative cracking of alkanes, such as hexane, to one or more olefins, such as ethylene, propylene, and/or butylene with improved alkane conversion and olefins product selectivity are also disclosed.

Abstract: Provided here are processes and systems for conversion of alkyl-bridged non-condensed alkyl multi-aromatic compounds to alkyl mono-aromatic compounds. One system includes a hydrodearylation reactor adapted to receive a hydrogen stream and a feed stream and to produce a reactor effluent stream in presence of a catalyst. The feed stream contains one or more of heavy alkyl aromatic compounds and one or more alkyl-bridged non-condensed alkyl multi-aromatic compounds. The reactor effluent stream contains one or more alkyl mono-aromatic compounds. The system also includes a first separator fluidly coupled to the hydrodearylation reactor and adapted to receive the reactor effluent stream and to produce a hydrodearylated gas stream and a hydrodearylated liquid stream. The system also includes a second separator fluidly coupled to the first separator and adapted to receive a portion of the hydrodearylated gas stream and to produce a hydrocarbon liquid stream and a vapor stream rich in hydrogen.

Abstract: This invention relates to processes and systems for converting acyclic hydrocarbons to alkenes, cyclic hydrocarbons and/or aromatics, for example converting acyclic C5 hydrocarbons to cyclopentadiene in a reactor system. The process includes contacting a feedstock comprising acyclic hydrocarbons with a catalyst material in at least one reaction zone to convert at least a portion of the acyclic hydrocarbons to a first effluent comprising alkenes, cyclic hydrocarbons and/or aromatics. A co-feed comprising H2, C1-C4 alkanes and/or C1-C4 alkenes may also be provided to the at least one reaction zone.

Abstract: Disclosed is a process for the conversion of acyclic C5 feedstock to a product comprising cyclic C5 compounds, including cyclopentadiene, and formulated catalyst compositions for use in such process. The process comprises contacting the feedstock and, optionally, hydrogen under acyclic C5 conversion conditions in the presence of a catalyst composition to form the product. The catalyst composition comprises a microporous crystalline metallosilicate, a Group 10 metal or compound thereof, a binder, optionally, a metal selected from the group consisting of rare earth metals, metals of Groups 8, 9, or 11, mixtures or combinations thereof, or a compound thereof, in combination with a Group 1 alkali metal or a compound thereof and/or a Group 2 alkaline earth metal or a compound thereof.

Abstract: Organic sulfur compounds contained in refinery off gas streams having either high ort low concentrations of olefins are converted to hydrogen sulfides which can be then be removed using conventional amine treating systems. The process uses a catalytic reactor with or without a hydrotreater depending on the olefin concentration of the off gas stream. The catalytic reactor operates in a hydrogenation mode or an oxidation mode to convert a majority of organic sulfur compounds into hydrogen sulfides.

Abstract: Processes and apparatuses for producing a C8 aromatic isomer product are provided. The processes comprise introducing a raffinate product stream comprising C8 aromatic isomers to an isomerization unit to provide an isomerized stream. The isomerized stream is separated to provide a first stream comprising C8 naphthenes and C7 aromatic hydrocarbons and a second stream comprising C8 aromatic isomers. The first stream is passed to an extractive distillation column to provide a recycle feedstream comprising the C8 naphthenes and an extract stream comprising the C7 aromatic hydrocarbons. The recycle feedstream is passed to the isomerization unit.

Abstract: An amorphous molecular material having stilbene and benzyl group substituents at both side of stilbene has fluorescent characteristics.

Abstract: The present invention is a solvent composition including: a solvent including 1-chloro-2,3,3-trifluoro-1-propene; and at least one type of stabilizer selected from a group consisting of phenols, ethers, epoxides, amines, alcohols, and hydrocarbons, and is a solvent composition which is excellent in solubility of various organic substances and has no adverse effect on a global environment, and is excellent in stability, and this solvent composition can be used for a wide range of industrial uses such as cleaning, coating uses, and a heat transfer fluid.

Abstract: The production of 2-propylheptanol described here is effected via Rh-catalyzed hydroformylation of C4-olefin to afford C5-aldehyde, aldol condensation to afford the C10-aldehyde and hydrogenation to afford the C10-alcohol. The emphasis is on the hydroformylation and the ligand employed therein. The problem addressed by the invention is that of reducing the costs of 2PH production. This problem is solved when a cheaper catalyst system which simultaneously achieves a better regioselectivity is employed in the hydroformylation.

Abstract: A method of converting methane to an oxygenate. The method includes converting methane to an oxygenate with a transition metal ion loaded zeolite catalyst in an aqueous medium in the presence of gaseous O2 and CO at a temperature lower than 200° C. Also disclosed are a two-metal ion zeolite catalyst for converting methane to methanol and a method for preparing the two-metal ion zeolite catalyst.

Abstract: The present invention relates to a composition for preventing or reducing microbial growth, particularly the growth of dermatophytic fungi, and/or aciduric and acidogenic gram-positive bacteria. More particularly, it relates to the use of trans-3,5,4?-trihydroxybibenzyl, also known as dihydro-resveratrol, or its dihydrostilbene derivatives and/or chemical variants as an anti-microbial agent. The present invention further relates to the management of dermatophytosis often caused by dermatophytic fungi and the management of dental caries often mediated by aciduric and acidogenic gram-positive Streptococci. The present invention therefore has applications in preventing, alleviating and/or treating dermatophytosis and dental caries.

Abstract: A method of producing alpha-tocotrienol quinone or a stereoisomer thereof, the method comprising selective opening of alpha-tocotrienol chroman to alpha-tocotrienol quinone in the presence of non-alpha tocotrienol chromans by oxidizing alpha-to-cotrienol with a metal salt oxidizing agent, wherein the stoichiometric ratio of metal salt oxidizing agent/alpha-tocotrienol is at least 4:1 and wherein said metal oxidizing agent is added in sequential additions, in order to reduce oxidation of any amounts of non-alpha tocotrienol chromans that might have been present in the starting alpha-tocotrienol chroman material. This process uses conditions favoring oxidation rates of the alpha tocotrienol chroman vs. the non-alpha tocotrienol chromans.

Abstract: The invention provides a method for preparing a carboxylic acid, which method includes the steps of providing magnesium carboxylate, wherein the carboxylic acid corresponding with the carboxylate has a solubility in water at 20° C. of 80 g/100 g water or less; acidifying the magnesium carboxylate with HCl, thereby obtaining a solution comprising carboxylic acid and magnesium chloride (MgCl2); optionally a concentration step, wherein the solution comprising carboxylic acid and MgCl2 is concentrated; precipitating the carboxylic acid from the solution comprising the carboxylic acid and MgCl2, thereby obtaining a carboxylic acid precipitate and a MgCl2 solution.

Abstract: A method of reducing the formation of an impurity in a terephthalic acid (TPA) production process includes: combining in a reactor, a catalyst, a mixture comprising the impurity and the TPA, and a compound comprising an active carbon atom; reacting the impurity with the compound in the presence of the catalyst by a condensation-dehydration reaction process comprising a nucleophilic addition of the active carbon atom of the compound to a carbonyl group of the impurity to form an intermediate followed by a dehydration reaction of the intermediate to form a product mixture comprising a water, the TPA, and an alkene; and recovering the product mixture from the reactor.

Abstract: Processes for continuous preparation of bioproducts are described herein. The processes include contacting fatty acid glycerides with alcohols in the presence of an acidic heterogeneous catalyst and separating the fatty acid alkyl esters from the reaction products.

Abstract: The patent discloses a process for the synthesis of dialkyl carbonates catalysed by a catalyst composition AB oxides, wherein A and B are rare earth metals or A and B are combination of rare earth and transition metals with ratios ranging from 0.5:10 to 10:0.5.

Abstract: The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I) preferably the salts thereof with hydrochloric or hydrobromic acid, particularly preferred the dichloride salt.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.

Abstract: The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.

Abstract: The invention relates to a process for purifying alkanesulfonic acids which comprises the steps of: (a) distilling a melt comprising crude alkanesulfonic acid (1) to completely or partly remove low boilers, wherein the low boilers are drawn off at the top of a distillation column (3) or of a one-stage evaporation apparatus and a material stream (7) comprising alkanesulfonic acid, high boilers and residual low boilers is withdrawn at the bottom of the distillation column (3) or of the one-stage evaporation apparatus, (b) sending the stream (7) comprising alkanesulfonic acid, high boilers and residual low boilers into a melt crystallization (9) as the starting melt to form crystals of the alkanesulfonic acid, of hydrates of the alkanesulfonic acid or of a mixture of both suspended in mother liquor, (c) performing a solid-liquid separation to remove the crystals from the mother liquor, (d) optionally washing the crystals to remove mother liquor adhering to the crystals.

Abstract: A radiation-sensitive resin composition includes a first polymer including a first structural unit that includes a first acid-labile group; a radiation-sensitive acid generator; and a compound represented by formula (1). n is 1 or 2. R1 represents a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms in a case in which n is 1. R1 represents a divalent organic group having 1 to 20 carbon atoms in a case in which n is 2. R2 represents a hydrogen atom or a monovalent organic group having 1 to 20 carbon atoms. E represents a group represented by formula (i). R2 and E may taken together represent a ring structure having 3 to 20 ring atoms together with the nitrogen atom. X represents a divalent organic group having 1 to 20 carbon atoms. R3 represents a second acid-labile group.

Abstract: The present invention relates to a new compound of formula (I) wherein the variables have the meaning as indicated in the claims; or an enantiomer or salt thereof. The compounds of formula (I) are useful in the control of parasites, in particular endoparasites, in and on vertebrates.

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g.

Abstract: The applicaton discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, R1R5, R6 and R7 are as defined herein.

Abstract: A process for the preparation of fluorinated compounds having at least one —OSF5 group, said method comprising the step of reacting SOF4 with a fluorinated 3- or 4-membered cyclic ether in the presence of a fluoride catalyst.

Abstract: Provided herein is a compound of Formula I: wherein R represents a terpene hydroperoxyl selected from the group consisting of wherein R? represents a alkyl group selected from the group consisting: CH3(CH2)8—, CH3(CH2)6—, and CH3—.

Abstract: An intermediate of the formula (I) wherein the radicals R1 are independently of one another methyl, ethyl or n-propyl, is suitable for preparing a compound of the formula (A) wherein X is a group of the formula (A-I) or (A-II), Y is C11-C17alkyl, and Z is a direct bond, —(CH2)8— or —CH2—S—CH2—. The compounds of the formula (A) are useful for stabilizing an organic material against thermal, oxidative or light induced degradation.

Abstract: Disclosed is a process for the synthesis of Pirfenidone (1) from 5-methyl-2(1H)-pyridinone and chlorobenzene in the presence of a catalytic system consisting of a copper salt and an organic ligand, in the presence of a base. The process exploits the high efficiency of the catalytic system consisting of copper(I) salt and an organic ligand in the presence of an inorganic base in the N-amidation reaction of chlorobenzene, a cheap reagent also usable as solvent in this case; reaction conditions at high temperatures, at atmosphere pressure or higher, produce a reaction with good yields.

Abstract: There are provided compounds of formula IIb, wherein: LG1 represents imidazolyl, chloro, or aryloxy; and Z1 represents a structural fragment of formula V: wherein R2 to R4, R5a, L and X1 to X3 have meanings given in the description, or a salt or protected derivative thereof, wherein said protected derivative is a compound in which the carboxyl moiety of R4 is protected as a C1-8 alkyl ester. The compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Abstract: The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.

Abstract: A fungicidal 4-methoxy-3-acetyloxypicolinamide may be conveniently prepared in processes that include the coupling together of 4-methoxy-3-acetyloxypicolinic acid or 4-methoxy-3-hydroxypicolinic acid with a key 2-aminopropanoate ester derived from a 1,1-bis(4-fluorophenyl)propane-1,2-diol.

Abstract: Compounds of formula (I) and salts are disclosed. Also disclosed are isotopes of compounds of formula I of the salts thereof. Pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using a compound of formula I are disclosed.

Abstract: Compounds represented by the following general formula (I), which has a P2X4 receptor antagonistic activity (in the formula, R1, R2 and R3 represent hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, a halogen atom, and the like, X represents C or N, Y represents N or C(?O), provided that when X is C, Y represents N, and when X is N, Y represents C(?O), the double line consisting of the solid line and the broken line represents a single bond or double bond, n represents an integer of 0 to 6, Z represents O, S, or an atomic bond, and A represents benzene ring, pyridine ring, and the like).

Abstract: Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.

Abstract: A thermodynamically stable crystal modification of 2-methyl-N-(5-methyl-1,3,4-oxadiazol-2-yl)-3-(methylsulfonyl)-4-(trifluoromethyl)benzamide is described. This thermodynamically stable crystal modification has particular advantages in the stability of suspension formulations.

Abstract: There is provided a polymerizable composition, by which discoloration or alignment defects are less likely to occur when a filmy polymer, which is obtained by adding a polymerizable compound to the polymerizable composition and polymerizing this composition, is irradiated with ultraviolet light. There are also provided a polymer obtained by polymerizing the polymerizable composition, and an optically anisotropic body using the polymer. The present invention provides a polymerizable low-wavelength dispersive or polymerizable reverse-wavelength dispersive compound having a partial structure represented by Formula (Z-0). Further, the present invention provides a composition containing the compound; a polymer obtained by polymerizing the composition; and an optically anisotropic body obtained by using the polymer.

Abstract: The invention relates to a method for obtaining glycidol in a semi-continuous or continuous manner by decarboxylating glycerol carbonate at reduced pressure, at a temperature less than or equal to 130° C. and in the presence of alkoxide catalysts of alkaline metals and alkaline earth metals, metal oxides, mixed metal oxides, metal stannates and mixed metal stannates, all of which optionally supported via SiO2, ?-Al2O3, MgO and ZrO2.

Abstract: The present invention is aimed to provide an industrially advantageous method for producing a furan compound, in which a furan compound can be efficiently obtained in a high selectivity from a furfural compound. The present invention is concerned with a method for producing a furan compound including feeding, as a raw material, a furfural composition containing a furfural compound into a reactor and subjecting to a decarbonylation reaction in the presence of a catalyst to obtain a furan compound as a product, wherein a furfural dimer concentration in the furfural composition is 1,000 ppm by weight or less, and a peroxide value in the furfural composition is 0.01 mEq/kg or more and 1.0 mEq/kg or less.

Abstract: Provided herein is a process for preparing furan-2,5-dicarboxylic acid. The process includes the following steps: (A-1) preparing a starting mixture comprising one, two or more carbohydrate compounds selected from the group consisting of: hexoses, oligosaccharides comprising hexose units, and polysaccharides including hexose units, and as a solvent or as a co-solvent for the carbohydrate compounds an amount of one or more carboxylic acid esters of a formula (II) and (A-2) subjecting the starting mixture to reaction conditions so that at least one of the one, two or more carbohydrate compounds reacts, and a fraction of the amount of one or more carboxylic acid esters of formula (II) is hydrolyzed, resulting in a mixture including 5-(hydroxymethyl)furfural and/or the one or more HMF esters of a formula (I), one or more carboxylic acids of a formula (III) and a remaining fraction of the amount of one or more carboxylic acid esters of formula (II).

Abstract: Provided herein is a process for preparing a mixture including 5-(hydroxy-methyl)furfural (HMF) and one or more HMF esters of formula (I), the process including the following steps: (A-1) preparing or providing a starting mixture which includes one, two or more carbohydrate compounds and as the solvent or as a co-solvent for the carbohydrate compounds an amount of one or more carboxylic acid esters of formula (II); (A-2) subjecting the starting mixture to reaction conditions so that at least one of the one, two or more carbohydrate compounds reacts, and a fraction of the amount of one or more carboxylic acid esters of formula (II) is hydrolyzed, so that a mixture results that includes 5-(hydroxy-methyl)furfural and/or the one or more HMF esters of formula (I), one or more carboxylic acids of formula (III) and a remaining fraction of the amount of one or more carboxylic acid esters of formula (II).

Abstract: The invention relates to a novel process for the conversion of a feedstock comprising at least one sugar to 5-hydroxymethylfurfural, in which said feedstock is contacted with one or more catalysts of the family of the homogeneous sulphonic acids in the presence of at least one aprotic polar solvent, used alone or in a mixture, at a temperature comprised between 30° C. and 200° C., and at a pressure comprised between 0.

Abstract: The present teachings relate to pyrone derivatives, pharmaceutical compositions thereof, and methods of using such compounds to treat bacterial infections.

Abstract: A compound having antihypertensive activity, especially 5-deoxy-irilin B having angiotensin-I-converting enzyme inhibition activity, derived from Salicornia SPP., a salty sauce containing the same, and a composition for the prevention and treatment of hypertension containing the same are provided. The Salicornia SPP.-derived salty sauce having superior sensory and functional properties can be produced through cutting or grinding and then hydrolyzing of Salicornia SPP.

Abstract: The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-halo-olivetol or derivative thereof with a suitably selected and substituted cyclic alkene to produce a dihalo-cannabidiol compound or derivative thereof. The dihalo-cannabidiol compound or derivative thereof can be produced in high yield, high stereospecificity, or both. It can then be converted under reducing conditions to a cannabidiol compound or derivatives thereof.

Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.

Abstract: The present invention generally relates to various dibenzothiophene compounds, processes for preparing these compounds, and use of these compounds in organic light-emitting diodes and as cellular imaging agents. In particular, the compounds of the present invention include various sulfoxide and sulfone analogs of various dibenzothiophene compounds. The present invention also relates to cell imaging agents comprising one or more of the dibenzothiophene compounds and processes for imaging a cell using the compounds. The present invention also relates to organic light-emitting diodes comprising one or more of the dibenzothiophene compounds and processes for preparing these organic light-emitting diodes.

Abstract: The invention relates to a cocrystal comprising a) at least bilastine and, b) at least a cocrystal forming compound selected from the group consisting of glutaric acid, adipic acid, sorbic acid, succinic acid, benzoic acid, 4-aminobenzoic acid, L-malic acid, resorcinol, methyl 4-hydroxy benzoate and N-(4-hydroxyphenyl)acetamide and mixtures thereof, or a solvate thereof. The invention further relates to methods for obtaining said cocrystals and to their use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases. The invention also relates to a method for increase the aqueous solubility of the above compounds of formula (I).